Pet

Novartis Animal Health adds Dasuquin®, a new breed of joint health supplement for dogs, broadening orthopaedic support for vets and pet owners

vetreportOctober 2, 2013

• Novartis Animal Health (NAH) is assuming marketing responsibilities for Dasuquin in the United Kingdom and Ireland, starting  1^st October 2013
• Dasuquin is an exclusive veterinary formulation with proprietary ingredients for advanced joint health support¹
• Dasuquin builds on  Novartis Animal Health’s current companion animal orthopaedic portfolio comprising Onsior^®   and Cosequin^®

1^st October – Novartis Animal Health, Inc. has assumed marketing responsibilities for the joint health supplement Dasuquin^® in the United Kingdom and Ireland, offering vets even broader support for the maintenance of orthopaedic health in dogs.

Dasuquin is an exclusive veterinary formulation developed to deliver advanced cartilage support in dogs. It contains the unique combination of glucosamine hydrochloride, chondroitin sulphate, avocado/soybean unsaponifiables (ASU), and tea polyphenols. These compounds work synergistically to protect the cartilage, thereby playing an important role in supporting and maintaining joint health.

The combination of ASU, chondroitin sulphate, and glucosamine hydrochloride delivers incremental benefits compared to the combination of chondroitin sulphate and glucosamine hydrochloride alone.¹

Dasuquin is conveniently available in tasty chewable tablets in 80-count containers. Dasuquin is available in two strengths: small-to-medium dogs weighing between 5 and 25 kg and for large dogs weighing over 25 to 50 kg.

“This is a fitting addition to our overall orthopaedic health offering for vets and pet owners,” said Gaynor Hillier, General Manager UK & Ireland Novartis Animal Health. “Dasuquin brings vets and dog owners advanced joint health support with the next generation of the popular Cosequin^® family.”

Dasuquin is available from Novartis Animal Health in the United Kingdom and Ireland from licensed veterinary wholesalers. For more information on Dasuquin and other Novartis Animal Health companion animal products and services, please contact your Novartis Animal Health Territory Manager

About Novartis Animal Health, Inc.

Headquartered in Basel, Switzerland, Novartis Animal Health, Inc. researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians in 40 countries around the world.  For more information about Novartis Animal Health, Inc., please consult http://www.ah.novartis.com.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Reference:

1. Au RY, Au AY, Rashmir-Raven A, et al. Inhibition of pro-inflammatory gene expression in chondrocytes, monocytes, and fibroblasts by the combination of avocado soybean unsaponifiables, glucosamine, and chondroitin sulfate. FASEB, 2007.